 Beneficial effects colestipol-niacin coronary atherosclerosis follow-up Cholesterol Lowering Atherosclerosis Study CLAS randomized placebo-controlled angiographic trial colestipol-niacin therapy subjects Two-year results CLAS-I decreased atherosclerosis progression increased regression subgroup subjects years CLAS-II Changes blood lipid lipoprotein-cholesterol apolipoprotein levels years drug-treated subjects nonprogression drug- vs placebo-treated regression drug- vs placebo-treated native coronary artery lesions drug-treated subjects new lesions native coronary arteries drug- vs placebo-treated bypass grafts drug- vs placebo-treated results CLAS-I findings regression years need early initiation vigorous long-term lipid therapy coronary bypass subjects